AQR Capital Management’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
Other funds holding CTKB
AQR Capital Management's CTKB Position: Q3 2026 in Review
AQR Capital Management increased its Cytek Biosciences (CTKB) stake by 62% in Q3 2026, buying an estimated $2.4M and bringing the position to 1,319,469 shares worth $7.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1737.
AQR Capital Management first reported a position in CTKB in Q3 2022 and has held it in 15 quarters since. 152 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.
- AQR Capital Management held 1,319,469 shares of Cytek Biosciences worth $7.86M as of Q3 2026.
- AQR Capital Management bought 505,498 Cytek Biosciences shares in Q3 2026, an estimated $2.4M.
- Cytek Biosciences made up ﹤0.01% of AQR Capital Management's portfolio in Q3 2026, its #1737 holding.
- AQR Capital Management first reported a position in Cytek Biosciences in Q3 2022 and has held it in 15 quarters since.
- 152 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.
Based on AQR Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.